Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditions
Open Access
- 19 October 2015
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 30 (2) , 688-701
Abstract
Autonomic dysfunction is a characteristic of cardiac disease and decreased vagal activity is observed in heart failure. Rodent cardiomyocytes produce de novo ACh, which is critical in maintaining cardiac homeostasis. We report that this nonneuronal cholinergic system is also found in human cardiomyocytes, which expressed choline acetyltransferase (ChAT) and the vesicular acetylcholine transporter (VAChT). Furthermore, VAChT expression was increased 3‐ and 1.5‐fold at the mRNA and protein level, respectively, in ventricular tissue from patients with heart failure, suggesting increased ACh secretion in disease. We used mice with genetic deletion of cardiomyocyte‐specific VAChT or ChAT and mice overexpressing VAChT to test the functional significance of cholinergic signaling. Mice deficient for VAChT displayed an 8% decrease in fractional shortening and 13% decrease in ejection fraction compared with angiotensin II (Ang II)‐treated control animals, suggesting enhanced ventricular dysfunction and pathologic remodeling in response to Ang II. Similar results were observed in ChAT‐deficient mice. Conversely, no decline in ventricular function was observed in Ang II‐treated VAChT overexpressors. Furthermore, the fibrotic area was significantly greater ( P < 0.05) in Ang II‐treated VAChT‐deficient mice (3.61 ± 0.64%) compared with wild‐type animals (2.24 ± 0.11 %). In contrast, VAChT overexpressing mice did not display an increase in collagen deposition. Our results provide new insight into cholinergic regulation of cardiac function, suggesting that a compensatory increase in cardiomyocyte VAChT levels may help offset cardiac remodeling in heart failure.—Roy, A., Dakroub, M., Tezini, G. C. S. V., Liu, Y., Guatimosim, S., Feng, Q., Salgado, H. C., Prado, V. F., Prado, M. A. M., Gros, R. Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditions. FASEB J. 30, 688‐701 (2016). www.fasebj.orgKeywords
Funding Information
- National Institutes of Health (R03TW008425)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo
This publication has 57 references indexed in Scilit:
- Stress‐inducible phosphoprotein 1 has unique cochaperone activity during development and regulates cellular response to ischemia via the prion proteinThe FASEB Journal, 2013
- Heart‐Specific Overexpression of Choline Acetyltransferase Gene Protects Murine Heart Against Ischemia Through Hypoxia‐Inducible Factor‐1α–Related Defense MechanismsJournal of the American Heart Association, 2013
- A Non-Neuronal Cardiac Cholinergic System Plays a Protective Role in Myocardium Salvage during Ischemic InsultsPLOS ONE, 2012
- An Analysis of the Myocardial Transcriptome in a Mouse Model of Cardiac Dysfunction with Decreased Cholinergic NeurotransmissionPLOS ONE, 2012
- Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophyJournal of Molecular and Cellular Cardiology, 2011
- Dysautonomia Due to Reduced Cholinergic Neurotransmission Causes Cardiac Remodeling and Heart FailureMolecular and Cellular Biology, 2010
- Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodentsJournal of Clinical Investigation, 2010
- New transport assay demonstrates vesicular acetylcholine transporter has many alternative substratesNeurochemistry International, 2005
- The pathway connecting m2 receptors to the nucleus involves small GTP-binding proteins acting on divergent map kinase cascadesLife Sciences, 1997
- Cholinergic Innervation of the Canine and Human Ventricular Conducting SystemCirculation, 1974